Evidence map›Paper›PMID 38746320›Full record

ArticlebioRxiv : the preprint server for biology2024

Rare germline structural variants increase risk for pediatric solid tumors.

Riaz Gillani, Ryan L Collins, Jett Crowdis, Amanda Garza, Jill K Jones, Mark Walker, Alba Sanchis-Juan, Chris Whelan, Emma Pierce-Hoffman, Michael Talkowski and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Riaz GillaniDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ryan L CollinsCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-1268-9995
Jett CrowdisHarvard Medical School, Boston, MA, USA.
Amanda GarzaCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Jill K JonesHarvard Medical School, Boston, MA, USA.
Mark WalkerData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alba Sanchis-JuanCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Chris WhelanData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Emma Pierce-HoffmanData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michael TalkowskiHarvard Medical School, Boston, MA, USA.
Harrison BrandHarvard Medical School, Boston, MA, USA.
Kevin HaigisCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-1922-4509
Jaclyn LoPiccoloCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Saud H AlDubayanCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Alexander GusevCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Brian D CromptonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katie A JanewayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eliezer M Van AllenCancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-0201-4444

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatmentK08CA276701 · NCI · DANA-FARBER CANCER INST · PI Riaz Gillani · 2023 to 2026
$788k
Dissecting the Role of Germline Genetics in RAS-Driven CancersK99CA286805 · NCI · DANA-FARBER CANCER INST · PI COLLINS, RYAN LEWIS · 2024 to 2025
$327k
NCI NIH HHS K08 CA276701NCI NIH HHS K99 CA286805NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA222574NCI NIH HHS U01 CA233100NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196173NHGRI NIH HHS T32 HG002295NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic factors are involved, yet conventional germline testing for short coding variants in established predisposition genes only identifies pathogenic events in 10-15% of patients. Here, we examined the role of germline structural variants (SVs)-an underexplored form of germline variation-in pediatric extracranial solid tumors using germline genome sequencing of 1,766 affected children, their 943 unaffected relatives, and 6,665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and a four-fold increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we revealed burdens of ultra-rare SVs that cause loss-of-function of highly expressed, mutationally intolerant, neurodevelopmental genes, as well as noncoding SVs predicted to disrupt three-dimensional chromatin domains in neural crest-derived tissues. Collectively, our results implicate rare germline SVs as a predisposing factor to pediatric solid tumors that may guide future studies and clinical practice.

Identifiers

PMID38746320
PMCPMC11092455

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.